Conclusions:
Age, ibrutinib dose, E/e’, and PALS on pre-treatment echocardiogram were
significantly associated with the development of IRAF. On multivariate
regression analysis, age, PALS and PACS remained significantly
associated with the development of IRAF. PALS may demonstrate an
age-dependent association with IRAF, whereas PACS may represent
age-independent loss of atrial contraction. Future studies are needed to
determine if this information can identify increased risk of IRAF, need
for enhanced surveillance, adjustment in anticoagulation management, and
possibly alternate oncologic therapies.